newsfilter
← Latest News
GlobeNewswire·

Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results

  • Kura Oncology will report fourth quarter & full year 2025 financial results on Thursday, March 5, 2026, before U.S. markets open.
  • Management will host a conference call & webcast at 8:00 a.m. ET / 5:00 a.m. PT to discuss results & provide a corporate update.
  • The live webcast & archived replay will be available on the Investors section of the company website at www.kuraoncology.com.
  • Kura is a biopharmaceutical company developing small molecule drug candidates targeting cancer signaling pathways for hematologic malignancies & solid tumors.
  • The company commercializes KOMZIFTI™, an FDA-approved once-daily oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia.
  • Kura continues to pioneer advancements in menin inhibition & farnesyl transferase inhibition.
  • Investor & media inquiries should contact Greg Mann at 858-987-4046 or gmann@kuraoncology.com.